Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

Overview of attention for article published in Clinical Cancer Research, May 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 12,989 followers.

@Martha__Carlson @Beatthemedian @SPMazrui @cancermedic @VeredStearns Yeah. It’s really interesting work. I think they are trying to figure out who would benefit from drugs like azacitidine. https://t.co/zUJujYmqXC

low RR to combo epigenetic therapy (AZA/HDACi) - only surprise is tolerable. Future for these drugs ?with IO https://t.co/sBbBNFIa0P

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Ca… https://t.co/s00XhD1ASW

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.